Bristol-Myers Squibb Company PFD CONV 2 Share · US1101222073 (OTC) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Bristol-Myers Squibb Company PFD CONV 2
No Price
Company Profile for Bristol-Myers Squibb Company PFD CONV 2 Share
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.
Company Data
Name Bristol-Myers Squibb Company PFD CONV 2
Company Bristol-Myers Squibb Company PFD CONV 2
Website
http://www.bms.com
Primary Exchange 
UTC
UTC
ISIN US1101222073
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - General
CEO Christopher S. Boerner
Market Capitalization 815 Mrd.
Country United States of America
Currency USD
Employees 34,1 T
Address , Princeton
IPO Date 2003-12-08
Dividends from 'Bristol-Myers Squibb Company PFD CONV 2'
| Ex-Date | Dividend per Share |
|---|---|
| 03.02.2026 | 0,50 USD |
| 04.11.2025 | 0,50 USD |
| 05.08.2025 | 0,50 USD |
| 06.05.2025 | 0,50 USD |
| 04.02.2025 | 0,50 USD |
| 05.11.2024 | 0,50 USD |
| 06.08.2024 | 0,50 USD |
| 06.05.2024 | 0,50 USD |
| 29.01.2024 | 0,50 USD |
| 30.10.2023 | 0,50 USD |
Ticker Symbols
| Name | Symbol |
|---|---|
| Over The Counter | BMYMP |
More Shares
Investors who hold Bristol-Myers Squibb Company PFD CONV 2 also have the following shares in their portfolio:
